Cybin Inc. Common Stock (HELP)

Price$5.61

Favorite Metrics

Price vs S&P 500 (26W)-18.93%

Price vs S&P 500 (4W)8.80%

Market Capitalization$1.40M

All Metrics

Book Value / Share (Quarterly)$4.02

Cash Flow / Share (Quarterly)$-1.75

Price vs S&P 500 (YTD)-35.86%

EPS (TTM)$-3.63

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-3.63

EPS (Annual)$-11.25

ROI (Annual)-88.81%

Gross Margin (Annual)23.11%

Cash / Share (Quarterly)$2.86

ROA (Last FY)-80.45%

EBITD / Share (TTM)$-3.55

Cash Flow / Share (Annual)$-3.50

P/B Ratio0.01x

P/B Ratio (Quarterly)2.11x

Net Income / Employee (Annual)$-1

Net Interest Coverage (TTM)-696.23x

ROA (TTM)-55.95%

EPS Incl Extra (Annual)$-11.25

Current Ratio (Annual)7.75x

Quick Ratio (Quarterly)12.44x

3-Month Avg Trading Volume0.01M

52-Week Price Return-26.83%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.57

P/S Ratio (Annual)2.22x

Asset Turnover (Annual)0.01x

52-Week High$12.70

EPS Excl Extra (Annual)$-11.25

26-Week Price Return-10.18%

Quick Ratio (Annual)6.71x

13-Week Price Return-31.76%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)13.78x

Enterprise Value$-141.512

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-3728.56%

Cash / Share (Annual)$3.18

3-Month Return Std Dev93.68%

Net Income / Employee (TTM)$-2

ROE (Last FY)-88.81%

Net Interest Coverage (Annual)-5.98x

EPS Basic Excl Extra (Annual)$-11.25

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.63

ROI (TTM)-60.13%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)-61.92%

Year-to-Date Return-32.49%

5-Day Price Return0.27%

EPS Normalized (Annual)$-11.25

Net Profit Margin (Annual)-3728.56%

Month-to-Date Return11.61%

EBITD / Share (Annual)$-11.21

Operating Margin (Annual)-3625.34%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.63

P/TBV (Quarterly)2.37x

Price vs S&P 500 (13W)-34.62%

Revenue / Share (TTM)$0.00

ROE (TTM)-65.64%

52-Week Low$5.90

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.14

4.25

About

Helus Pharma is a clinical-stage biopharmaceutical company developing serotonergic agonists to treat mental health disorders, including depression and anxiety. The company's lead candidate, HLP003, is in Phase 3 development for adjunctive treatment of major depressive disorder. With operations across North America and Europe, Helus Pharma addresses an underserved market for innovative neuropsychiatric therapies.